Developer docs
API playgroundTry for free, no card

Search company profiles

Entasis Therapeutics

Full company profile

uuid0005mw6

Namestring
Entasis Therapeutics
Legal namestring
Entasis Therapeutics
Websiteurl
entasistx.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Entasis Therapeutics is a clinical-stage biopharmaceutical company that developed novel anti-infective therapies targeting serious, life-threatening infections caused by drug-resistant microorganisms, with particular focus on critical care and hospital-acquired infections. Founded in 2015 and headquartered in Waltham, Massachusetts, the company built a portfolio around proprietary small-molecule approaches to overcoming bacterial resistance, most notably XACDURO (sulbactam-durlobactam), an FDA-approved antimicrobial combination therapy for the treatment of Acinetobacter baumannii-calcoaceticus complex infections. The company raised approximately $199.5 million across multiple private and public funding rounds between 2015 and 2021, with investors including Clarus Ventures, Eventide, Frazier Healthcare Partners, Novo Holdings, Pivotal bioVenture Partners, Sofinnova Investments, TPG, and CARB-X.

The company was acquired by Innoviva, Inc. (NASDAQ: INVA), a diversified holding company that manages royalty streams from GlaxoSmithKline respiratory drugs (Trelegy Ellipta, Breo Ellipta) and reinvests those proceeds into specialty therapeutics acquisitions. Following the acquisition, Entasis operates as part of Innoviva Specialty Therapeutics, whose broader marketed portfolio includes GIAPREZA, NUZOLVENCE, XACDURO, XERAVA, and ZEVTERA. Products are distributed through traditional specialty pharmaceutical channels targeting hospital and clinical settings, with marketing and medical affairs activities focused on healthcare professional engagement and scientific exchange. The company's value proposition centers on addressing high-unmet-need infectious diseases identified as urgent threats by leading global public health organizations, with the Acinetobacter treatment market projected to reach $1.25 billion by 2032.

Short descriptiontext

Entasis Therapeutics develops novel anti-infective therapies for drug-resistant infections, including the FDA-approved XACDURO for Acinetobacter. Now operating as a subsidiary of Innoviva Specialty Therapeutics following acquisition by Innoviva.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
anti-infective therapeutics, critical care pharmaceuticals, drug-resistant infection treatments, specialty biopharmaceuticals, hospital antimicrobial therapies
Industry1 code
1Respiratory & Allergy Pharmaceuticals
CodeHLAIAAAHPrimaryYes
NAICS code1 code
  • Health Care and Social Assistance62
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Anti-Infective Pharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Specialty Pharmaceutical Products
TypeOne Time License
Description

Revenue generated from the sale of specialty pharmaceutical products for critical care and infectious diseases, including products like Giapreza and Xacduro that were acquired through the company's acquisition by Innoviva.

investors.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Entasis Therapeutics develops and delivers specialty anti-infective pharmaceutical products targeting critical care and infectious disease, with a focus on therapies for serious, life-threatening infections caused by drug-resistant microorganisms. Its marketed products include XACDURO (sulbactam-durlobactam), GIAPREZA (angiotensin II), NUZOLVENCE (zoliflodacin), XERAVA (eravacycline), and ZEVTERA (ceftobiprole), now commercialized through Innoviva Specialty Therapeutics following Innoviva's acquisition of Entasis.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Entasis Therapeutics was a clinical-stage biopharmaceutical company focused on developing novel anti-infective products. The company was acquired by Innoviva (INVA), and its products including XACDURO are now marketed through Innoviva Specialty Therapeutics. The product portfolio includes therapies for critical care and infectious diseases caused by drug-resistant microorganisms.

Product and service5 records
1XACDURO (sulbactam for injection; durlobactam for injection)
CategoryAnti-Infective Pharmaceutical
Description

FDA-approved antimicrobial therapy combining sulbactam and durlobactam, developed to treat drug-resistant Acinetobacter baumannii-calcoaceticus complex infections in hospital and critical care settings. It is marketed through Innoviva Specialty Therapeutics and is for healthcare providers treating serious, life-threatening infections.

2GIAPREZA (angiotensin II)
CategoryCritical Care Pharmaceutical
Description

Critical care therapy for adult patients with distributive shock, marketed through Innoviva Specialty Therapeutics to hospital and clinical settings.

3NUZOLVENCE (zoliflodacin)
CategoryAnti-Infective Pharmaceutical
Description

Anti-infective therapy within the Innoviva Specialty Therapeutics portfolio for serious infectious diseases, distributed through standard hospital and clinical pharmaceutical channels.

4XERAVA (eravacycline)
CategoryAnti-Infective Pharmaceutical
Description

Anti-infective therapy within the Innoviva Specialty Therapeutics portfolio, distributed through standard hospital and clinical pharmaceutical channels for treatment of serious infections.

5ZEVTERA (ceftobiprole medocaril sodium for injection)
CategoryAnti-Infective Pharmaceutical
Description

Anti-infective therapy within the Innoviva Specialty Therapeutics portfolio, distributed through standard hospital and clinical pharmaceutical channels for serious infectious disease indications.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Entasis Therapeutics

Anti-Infective Pharmaceuticalsentasistx.com

Entasis Therapeutics develops novel anti-infective therapies for drug-resistant infections, including the FDA-approved XACDURO for Acinetobacter. Now operating as a subsidiary of Innoviva Specialty Therapeutics following acquisition by Innoviva.

What Entasis Therapeutics does

Entasis Therapeutics is a clinical-stage biopharmaceutical company that developed novel anti-infective therapies targeting serious, life-threatening infections caused by drug-resistant microorganisms, with particular focus on critical care and hospital-acquired infections. Founded in 2015 and headquartered in Waltham, Massachusetts, the company built a portfolio around proprietary small-molecule approaches to overcoming bacterial resistance, most notably XACDURO (sulbactam-durlobactam), an FDA-approved antimicrobial combination therapy for the treatment of Acinetobacter baumannii-calcoaceticus complex infections. The company raised approximately $199.5 million across multiple private and public funding rounds between 2015 and 2021, with investors including Clarus Ventures, Eventide, Frazier Healthcare Partners, Novo Holdings, Pivotal bioVenture Partners, Sofinnova Investments, TPG, and CARB-X.

The company was acquired by Innoviva, Inc. (NASDAQ: INVA), a diversified holding company that manages royalty streams from GlaxoSmithKline respiratory drugs (Trelegy Ellipta, Breo Ellipta) and reinvests those proceeds into specialty therapeutics acquisitions. Following the acquisition, Entasis operates as part of Innoviva Specialty Therapeutics, whose broader marketed portfolio includes GIAPREZA, NUZOLVENCE, XACDURO, XERAVA, and ZEVTERA. Products are distributed through traditional specialty pharmaceutical channels targeting hospital and clinical settings, with marketing and medical affairs activities focused on healthcare professional engagement and scientific exchange. The company's value proposition centers on addressing high-unmet-need infectious diseases identified as urgent threats by leading global public health organizations, with the Acinetobacter treatment market projected to reach $1.25 billion by 2032.

Entasis Therapeutics firmographics

Firmographics
Name
Entasis Therapeutics
Legal name
Entasis Therapeutics
Website
https://entasistx.com
Company type
Private
Founded year
2015
Operating status
Acquired
Headcount range
51–100 employees
Short description
Entasis Therapeutics develops novel anti-infective therapies for drug-resistant infections, including the FDA-approved XACDURO for Acinetobacter. Now operating as a subsidiary of Innoviva Specialty Therapeutics following acquisition by Innoviva.
Ownership category
akta.pro rank

Entasis Therapeutics industry classification

Industry
Product category
Anti-Infective Pharmaceuticals
NAICS
Health Care and Social Assistance (62)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

Keywords

  • Anti-infective therapeutics
  • Critical care pharmaceuticals
  • Drug-resistant infection treatments
  • Specialty biopharmaceuticals
  • Hospital antimicrobial therapies

Where Entasis Therapeutics is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Markets served

Entasis Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Specialty Pharmaceutical Products: Revenue generated from the sale of specialty pharmaceutical products for critical care and infectious diseases, including products like Giapreza and Xacduro that were acquired through the company's acquisition by Innoviva.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Entasis Therapeutics product offering

Product offering

Core offering

Entasis Therapeutics develops and delivers specialty anti-infective pharmaceutical products targeting critical care and infectious disease, with a focus on therapies for serious, life-threatening infections caused by drug-resistant microorganisms. Its marketed products include XACDURO (sulbactam-durlobactam), GIAPREZA (angiotensin II), NUZOLVENCE (zoliflodacin), XERAVA (eravacycline), and ZEVTERA (ceftobiprole), now commercialized through Innoviva Specialty Therapeutics following Innoviva's acquisition of Entasis.

Product overview

Entasis Therapeutics was a clinical-stage biopharmaceutical company focused on developing novel anti-infective products. The company was acquired by Innoviva (INVA), and its products including XACDURO are now marketed through Innoviva Specialty Therapeutics. The product portfolio includes therapies for critical care and infectious diseases caused by drug-resistant microorganisms.

Differentiator

Problem solved

Functional benefit

Products and services

  • XACDURO (sulbactam for injection; durlobactam for injection) FDA-approved antimicrobial therapy combining sulbactam and durlobactam, developed to treat drug-resistant Acinetobacter baumannii-calcoaceticus complex infections in hospital and critical care settings. It is marketed through Innoviva Specialty Therapeutics and is for healthcare providers treating serious, life-threatening infections.
  • GIAPREZA (angiotensin II) Critical care therapy for adult patients with distributive shock, marketed through Innoviva Specialty Therapeutics to hospital and clinical settings.
  • NUZOLVENCE (zoliflodacin) Anti-infective therapy within the Innoviva Specialty Therapeutics portfolio for serious infectious diseases, distributed through standard hospital and clinical pharmaceutical channels.
  • XERAVA (eravacycline) Anti-infective therapy within the Innoviva Specialty Therapeutics portfolio, distributed through standard hospital and clinical pharmaceutical channels for treatment of serious infections.
  • ZEVTERA (ceftobiprole medocaril sodium for injection) Anti-infective therapy within the Innoviva Specialty Therapeutics portfolio, distributed through standard hospital and clinical pharmaceutical channels for serious infectious disease indications.

Companies that use Entasis Therapeutics

Customer profile

Segments2 records

Ideal customer profiles1 record

Entasis Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Entasis Therapeutics partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Entasis Therapeutics competitors and assessment

Company assessment

Market position

Competitive moat4 records

Customer concentration

Entasis Therapeutics social profiles

Digital presence

Entasis Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Entasis Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

Entasis Therapeutics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Entasis Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Entasis Therapeutics

What does Entasis Therapeutics do?

Entasis Therapeutics develops and delivers specialty anti-infective pharmaceutical products targeting critical care and infectious disease, with a focus on therapies for serious, life-threatening infections caused by drug-resistant microorganisms. Its marketed products include XACDURO (sulbactam-durlobactam), GIAPREZA (angiotensin II), NUZOLVENCE (zoliflodacin), XERAVA (eravacycline), and ZEVTERA (ceftobiprole), now commercialized through Innoviva Specialty Therapeutics following Innoviva's acquisition of Entasis.

Is Entasis Therapeutics a public or private company?

Entasis Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was Entasis Therapeutics founded?

Entasis Therapeutics was founded in 2015. It employs 51 to 100 people.

Where is Entasis Therapeutics based?

Entasis Therapeutics is headquartered in Waltham, United States, in the North America region.

How does Entasis Therapeutics make money?

One revenue line is on record: specialty Pharmaceutical Products.

Does Entasis Therapeutics have an API?

No public API is recorded for Entasis Therapeutics.

What industry is Entasis Therapeutics in?

Entasis Therapeutics's product category is Anti-Infective Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAH, Respiratory & Allergy Pharmaceuticals. Its NAICS code is 62 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InvestorsAnalysts See This Pharma Stock Surging 60%; Eyes Fresh EntryAnalysts have set a consensus "strong buy" rating on Innoviva (INVA) with an average price target of $37, representing approximately 60% upside from current levels, as the pharma company builds a bullish base despite broader market pressure. The company manages royalty streams from GlaxoSmithKline respiratory drugs including Trelegy Ellipta and Breo Ellipta while reinvesting in specialty therapeutics through acquisitions such as Jolla Pharmaceutical and Entasis Therapeutics, with products including Giapreza and Xacduro. Institutional investors have been accumulating shares, with funds holding 66% of outstanding shares, while the company's royalty portfolio has declined from 72% of revenue in 2024 to just over 60%, though analysts project earnings will recover with 15% growth in 2027 following an expected 42% decline this year.InvestorsAnalysts See This Pharma Stock Surging 60%; Eyes Fresh EntryAnalysts are projecting Innoviva (INVA) stock could surge approximately 60% from current levels, with a consensus price target of $37 and a strong buy rating on TipRanks. The company, which originally managed royalty streams from respiratory drugs co-developed with GlaxoSmithKline including Trelegy Ellipta and Breo Ellipta, has been reinvesting those funds into acquiring specialty therapeutics companies like Jolla Pharmaceutical and Entasis Therapeutics. While the royalty portfolio's share of revenue has declined from 72% in 2024 to just over 60%, and full-year earnings are projected to fall 42% this year before rebounding 15% in 2027, analysts note the stock has formed a flat base with a buy point at 25.14 and institutional investors hold 66% of shares.openPR.comHospital-Acquired And Ventilator-Associated Bacterial Pneumonia Market Size in the 7MM is expected to grow at a significant CAGR by 2034, estimates DelveInsightDelveInsight released a market insights report projecting significant CAGR growth for the Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) market across the 7 Major Markets (US, EU4, UK, Japan) through 2034, with the US reporting the highest incident cases in 2024. The report covers marketed therapies including XACDURO (Innoviva, approved May 2023 following its acquisition of Entasis Therapeutics) and FETROJA (Shionogi), as well as emerging candidates in clinical development such as AR-301 (Aridis Pharmaceuticals, Phase III) and BV100 (Bioversys, Phase II). Key pathogens driving HABP/VABP include S.aureus, P.aeruginosa, Klebsiella, E.coli, Acinetobacter species, and Enterobacter species, with antibiotic resistance limiting current treatment effectiveness.PR NewswireGonorrhea Therapeutics Market size is set to grow by USD 541.5 million from 2024-2028, Rising prevalence of gonorrhea boost the market, TechnavioTechnavio's latest market research report projects the global gonorrhea therapeutics market will grow by USD 541.5 million from 2024-2028, expanding at a CAGR of 5.55% due to the rising prevalence of gonorrhea infections and increasing antibiotic resistance. North America is expected to contribute 40% of market growth, supported by CDC funding through programs like SURRG that enhance surveillance and genomic sequencing to combat resistant strains. Key companies operating in this market include Apotex Inc., Aurobindo Pharma Ltd., Bristol Myers Squibb Co., Cipla Inc., and Entasis Therapeutics, which is developing the novel treatment Zoliflodacin.BenzingaAstraZeneca-Spin Off Entasis Secures FDA Approval For First Pathogen-Targeted Therapy Addressing AcinetobEntasis Therapeutics Inc, an affiliate of Innoviva Inc, received FDA approval for Xacduro (sulbactam and durlobactam) to treat hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex in patients 18 years and older. The drug demonstrated non-inferiority to colistin in a Phase 3 ATTACK trial regarding 28-day all-cause mortality. Innoviva acquired Entasis in May 2022 for $2.20 per share, and the company anticipates Xacduro will be available to patients later this year.PR NewswireFDA Approves New Treatment for Pneumonia Caused by Certain Difficult-to-Treat BacteriaThe FDA approved Xacduro (sulbactam/durlobactam), a new intravenous treatment for hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex in patients 18 years and older. In a clinical trial of 177 hospitalized adults with carbapenem-resistant A. baumannii pneumonia, Xacduro demonstrated non-inferiority to colistin with lower mortality (19% vs 32%). The FDA granted approval to Entasis Therapeutics, addressing a critical unmet medical need as Acinetobacter is classified by the WHO as the top priority bacterial pathogen threatening human health.BenzingaOver $42 Million Bet On This Biotechnology Stock? 4 Penny Stocks Insiders are Buying - Camp4 TherapeuticsThe article reports on notable insider trading activities for several penny stocks, highlighting acquisitions by SeaChange International, Entasis Therapeutics, and CalAmp. These transactions are presented as indicators of insider confidence despite recent corporate developments such as terminated mergers or missed earnings expectations. The content aggregates these specific financial events to guide investor decisions regarding small-cap equities.Business Wire BlogInnoviva Completes Acquisition of Entasis TherapeuticsInnoviva, Inc. has completed its acquisition of Entasis Therapeutics Holdings Inc., making Entasis a wholly-owned subsidiary after satisfying all tender offer conditions. The transaction was executed at $2.20 per share and provides Innoviva with Entasis's pipeline, including the lead asset SUL-DUR for multidrug-resistant bacteria. Innoviva plans to submit a New Drug Application for SUL-DUR to the U.S. Food and Drug Administration in the third quarter of 2022.BioSpaceInnoviva Completes Acquisition of Entasis TherapeuticsInnoviva Inc. has completed its acquisition of Entasis Therapeutics Holdings Inc., making Entasis a wholly-owned subsidiary after satisfying all tender offer conditions. The transaction involves Innoviva acquiring all outstanding equity securities of Entasis for $2.20 per share, gaining access to Entasis's pipeline including the lead asset SUL-DUR. Innoviva expects to submit a New Drug Application for SUL-DUR to the FDA in the third quarter of 2022.PR NewswireSHAREHOLDER UPDATE: Halper Sadeh LLP Investigates PCSB, STON, ETTX, CTEKHalper Sadeh LLP, an investor rights law firm, announced investigations into four pending mergers for potential violations of federal securities laws and breaches of fiduciary duties to shareholders. The four acquisitions under scrutiny are: PCSB Financial Corporation's sale to Brookline Bancorp, Inc.; StoneMor Inc.'s sale to Axar Capital Management, LP; Entasis Therapeutics Holdings Inc.'s sale to Innoviva, Inc.; and CynergisTek, Inc.'s sale to Clearwater Compliance LLC. The law firm is contacting shareholders of the target companies to inform them of their legal rights and options, and may seek increased consideration or additional disclosures on behalf of shareholders.